Citigroup
CNCR

Citigroup’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Citigroup’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,092
Closed -$32K – 5886
2022
Q2 		$32K Sell
2,092
-30
-1% -$460 ﹤0.01% 4751
2022
Q1 		$38K Sell
2,122
-3,045
-59% -$57.8K ﹤0.01% 4848
2021
Q4 		$123K Sell
5,167
-958
-16% -$26.6K ﹤0.01% 4627
2021
Q3 		$186K Sell
6,125
-3,542
-37% -$107K ﹤0.01% 4150
2021
Q2 		$308K Buy
9,667
+1,690
+21% +$51K ﹤0.01% 4007
2021
Q1 		$238K Buy
7,977
+172
+2% +$5.6K ﹤0.01% 3926
2020
Q4 		$248K Sell
7,805
-999
-11% -$30K ﹤0.01% 4826
2020
Q3 		$241K Buy
8,804
+8
+0.1% +$214 ﹤0.01% 4480
2020
Q2 		$240K Sell
8,796
-1,672
-16% -$41.1K ﹤0.01% 4876
2020
Q1 		$208K Sell
10,468
-2,301
-18% -$49.6K ﹤0.01% 4694
2019
Q4 		$299K Buy
12,769
+1,684
+15% +$35.7K ﹤0.01% 4852
2019
Q3 		$206K Sell
11,085
-390
-3% -$7.92K ﹤0.01% 5128
2019
Q2 		$242K Buy
11,475
+3,902
+52% +$80.3K ﹤0.01% 5100
2019
Q1 		$159K Buy
7,573
+373
+5% +$7.83K ﹤0.01% 5314
2018
Q4 		$136K Buy
7,200
+1,000
+16% +$20.8K ﹤0.01% 5391
2018
Q3 		$154K Sell
6,200
-800
-11% -$19.7K ﹤0.01% 5488
2018
Q2 		$169K Buy
+7,000
New +$189K ﹤0.01% 5223
2018
Q1 		– Sell
-1,000
Closed -$24K – 7554
2017
Q4 		$24K Buy
+1,000
New +$25.3K ﹤0.01% 6636

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Citigroup's CNCR Position: Q3 2022 in Review

Citigroup sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2022, closing a stake of 2,092 shares — an estimated $32K sold.

Citigroup first reported a position in CNCR in Q4 2017 and held it in 18 quarters. The position peaked at $308K in Q2 2021. 19 funds tracked by Wall St. Rank hold CNCR as of Q3 2022.

  • Citigroup reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 2,092 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2022, an estimated $32K.
  • Citigroup first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2017 and held it in 18 quarters.
  • Citigroup's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $308K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.